Living with a heart that struggles to pump effectively creates daily challenges for millions of Americans. Systolic heart ...

Researchers report a discovery in cardiac regeneration that offers new hope for the treatment of ischemic heart failure.

Ajax Health announced today that, with Boston Scientific and KKR, it formed a new medical technology entity called FlowMod.

The discovery of a novel approach to promote cardiomyocyte proliferation offers new hope for the treatment of ischemic heart failure.

By Karen Roman Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction. Additionally, ...

The global Heart Failure Drugs Market is valued at $8.6 billion in 2024 and is projected to reach a value of $21.4 billion by 2035. This growth represents a Compound Annual Growth Rate (CAGR) of 12.1% ...

There are medications to treat one of the two main types of heart failure, but they aren’t used as much as they should be, doctors said. “The treatments that have been proven in trials to work ...

A widely used diabetes medication, SGLT2 inhibitors, has shown a surprising benefit for cancer patients—protecting their ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

The patient, a man in his 40s from New South Wales, received the BiVACOR Total Artificial Heart (TAH) during a six-hour ...

SGLT2 inhibitors, a diabetes medication, may protect the heart and reduce hospitalizations for cancer patients, particularly ...

TULSA, Okla. — Some people with congestive heart failure are getting the chance to try a new treatment. Saint Francis is in the middle of a two-year double-blind clinical trial for a device ...